Henri Termeer in his Genzyme days. (Globe file)
Two members of the board of biotechnology start-up Verastem Inc. have made large purchases of the Cambridge company’s common stock, according to regulatory filings.
Lead director Henri A. Termeer, the retired chief executive of Genzyme Corp., bought 11,356 shares of Verastem at $9.35 apiece, a filing with the Securities and Exchange Comission said. A separate SEC filing said director John K. Clarke, co-founder of venture capital firm Cardinal Partners, bought 25,000 shares of Verastem at $9.21 a share, lifting his holdings to 2,305,959 shares.
Verastem board chairman Christoph Westphal, who will be stepping down as chief executive July 1, is the company’s largest shareholder, owning 17.5 percent of its stock as of April 25—both through personal holdings and as part of his partnership at Boston venture firm Longwood Fund. Westphal continues to add shares at regular intervals through a stock-buying plan.
Westphal will be replaced as Verastem’s chief executive by Robert Forrester, who currently serves as the company’s president and chief operating officer.